Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Nanoparticle Gold-Filled Silicon Wafers Effectively Kill Breast Cancer Cells

By BiotechDaily International staff writers
Posted on 02 Feb 2012
Print article
Heat generated when hollow gold nanoparticles embedded in silicon nanowafers were exposed to infrared light effectively killed breast cancer cells in vitro and in a mouse model.

Investigators at The Methodist Hospital Research Institute (Houston, TX, USA) created the highly efficient thermal transfer nanoparticles by confining gold nanoshells into nanopores of silicon microparticles. In the presence of infrared light at 808 nm, the gold-filled silicon particles heated up a surrounding aqueous solution by about 20 °C in seven minutes.

Hollow gold responds to near-infrared (NIR) light, which is able to penetrate deeply inside the body and which causes less damage to tissues compared to shorter wavelength light due to less absorbance by the tissue chromophores.

The investigators used human and mouse breast-cancer lines to test cell killing in vitro and the mouse model of 4T1 mammary tumor for in vivo studies. They reported in the January 3, 2012, online edition of the journal Advanced Healthcare Materials that the nanoparticles effectively killed cancer cells both in vitro and in the mouse model.

“Hollow gold nanoparticles can generate heat if they are hit with a near-infrared laser,” said first author Dr. Haifa Shen, assistant research member at The Methodist Hospital Research Institute. “Multiple investigators have tried to use gold nanoparticles for cancer treatment, but the efficiency has not been very good – they would need a lot of gold nanoparticles to treat a tumor. We found that heat generation was much more efficient when we loaded gold nanoparticles into porous silicon, the carrier of the multistage vectors.”

“The hollow gold particles we load into the porous silicon must be the right size and have the correct-sized space inside them to interact with the infrared light we are using,” said Dr. Shen. “But the wavelength of infrared we use will have to change depending on where the tumor is. If it is close to the skin, we can use shorter wavelengths. Deeper inside the body, we have to use longer wavelengths of infrared to penetrate the tissue. The hollow space of the gold particles must be modified in response to that. We are planning preclinical studies to study the technology's impact on whole tissues, breast cancer cells, and possibly pancreatic cancer cells. We would also like to see whether this approach makes chemotherapy more effective, meaning you could use less drugs to achieve the same degree of success in treating tumors. These investigations are next.”

Related Links:

The Methodist Hospital Research Institute


Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.